Extract of Cimicifuga racemosa (Black cohosh) Ze 450

Consumer Medicine Information

What is in this leaflet?

The information in this leaflet will answer some of the questions you may have about Femular tablets.

What Femular tablets are used for

Femular tablets are recommended for the relief of menopausal symptoms such as hot flushes, sweating, sleep disorders and nervous irritability.


Known hypersensitivity to Black cohosh or to any of the tablet ingredients.

How to take Femular tablets

Femular tablets are taken one tablet daily.

The onset of action can be expected within 2-4 weeks with a maximal effect felt within 3 months. There is no restriction on the duration of treatment. If symptoms persist, medical advice should be sought.

Special warnings and precautions for use

None required. Femular is only used by women with menopausal symptoms, it is not intended to be used during pregnancy and lactation.

Interaction with other medicines

None reported.

Side effects

Occasional gastrointestinal disturbances have been reported.


No cases of overdose have been reported.


Femular tablets should be stored in their original packaging, be protected from moisture and sunlight and kept in a cool place that stays below 25°C.

Product Description

Each Femular tablet contains extracts equivalent to dry:

  • Cimicifuga racemosa rhizome 42.25mg

Femular tablets contain lactose.


Femular is made in Switzerland by Zeller AG and is marketed by
herbal medicines
Level 5, 156 Pacific Highway
St. Leonards NSW 2065 Australia
Telephone: 02 9431 7200
Fax: 02 9431 7272

Adapted from 41919 11/2005A

Published by MIMS August 2010

Consumers should be aware that the information provided by the Consumer Medicines Information (CMI) search (CMI Search) is for information purposes only and consumers should continue to obtain professional advice from a qualified healthcare professional regarding any condition for which they have searched for CMI. CMIs are provided by MIMS Australia. CMI is supplied by the relevant pharmaceutical company for each consumer medical product. All copyright and responsibility for CMI is that of the relevant pharmaceutical company. MIMS Australia uses its best endeavours to ensure that at the time of publishing, as indicated on the publishing date for each resource (e.g. Published by MIMS/myDr January 2007), the CMI provided was complete to the best of MIMS Australia's knowledge. The CMI and the CMI Search are not intended to be used by consumers to diagnose, treat, cure or prevent any disease or for any therapeutic purpose. Dr Me Pty Limited, its servants and agents shall not be responsible for the continued currency of the CMI, or for any errors, omissions or inaccuracies in the CMI and/or the CMI Search whether arising from negligence or otherwise or from any other consequence arising there from.